89bio reports fourth quarter and full year 2024 financial results and corporate updates

– enlighten-fibrosis and enlighten-cirrhosis phase 3 trials in patients with non-cirrhotic (f2-f3) and compensated cirrhotic (f4) metabolic dysfunction-associated steatohepatitis (mash) continue to advance with topline histology data expected in 1h 2027 and 2028, respectively – –the phase 3 entrust trial in severe hypertriglyceridemia (shtg) will be unblinded after study completion at week 52 vs. week 26 following discussions with the u.s. food and drug administration (fda); topline data are now expected in 1q 2026 – – cash, cash equivalents, and marketable securities totaled $440.0 million as of december 31, 2024; a follow-on offering in the 1q 2025 resulted in gross proceeds of $287.5 million – san francisco, feb. 27, 2025 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the fourth quarter and full year ended december 31, 2024, and provided corporate updates.
ETNB Ratings Summary
ETNB Quant Ranking